Who Supplies Clindamycin to India from GREECE

To import finished pharmaceutical formulations containing Clindamycin (HS Code 30042095) into India, the following regulatory steps are mandatory:

1. 1Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation (CDSCO). This involves submitting Form 40 or 41, along with the necessary documentation, to the CDSCO.
3. 3Drug Approval: Secure approval from the Drug Controller General of India (DCGI) for the specific formulation.
4. 4No Objection Certificate (NOC): If the product is already marketed in India, an NOC from the manufacturer is required.

The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory workload.

Imported Clindamycin formulations must undergo quality testing to ensure compliance with Indian standards:

1. 1Testing Laboratories: Samples are tested in CDSCO-approved laboratories to verify quality, purity, and potency.
2. 2Batch Certification: Each batch requires a Certificate of Analysis (CoA) from the manufacturer, detailing the composition and quality parameters.
3. 3Stability Data: Stability studies must be conducted under ICH Zone IV conditions to assess the product's shelf life in India's climate.
4. 4Pharmacopoeia Compliance: Formulations must adhere to the standards set by the Indian Pharmacopoeia.

Upon arrival, customs drug inspectors perform port inspections to verify compliance with these requirements.

Between 2024 and 2026, India has implemented several regulatory updates affecting the import of finished pharmaceutical formulations:

1. 1CDSCO Updates: Revisions to import guidelines have streamlined the registration process, reducing approval times.
2. 2PLI Scheme Impact: The Production Linked Incentive (PLI) scheme has incentivized domestic production, potentially affecting the volume of imports.
3. 3Bilateral Agreements: India has engaged in discussions with Greece to facilitate smoother trade, including mutual recognition of Good Manufacturing Practices (GMP).

These changes aim to balance the promotion of domestic manufacturing with the need for high-quality imported pharmaceuticals.

India imports finished Clindamycin formulations to meet the demand for specific dosage forms and branded products not available domestically. The market size for Clindamycin formulations in India is substantial, with a growing need for both oral and topical applications. Domestic manufacturers may lack the capacity or technology to produce certain specialized formulations, leading to reliance on imports.

The import duty structure for Clindamycin formulations (HS Code 30042095) in India is as follows:

1. 1Basic Customs Duty (BCD): 10%
2. 2Social Welfare Surcharge (SWS): 10% of the BCD
3. 3Integrated Goods and Services Tax (IGST): Applicable as per the prevailing GST rates for pharmaceuticals

There are no additional duties or exemptions specified for this product category. The total landed duty percentage varies based on the CIF value and applicable IGST rates.

India sources Clindamycin formulations from Greece due to several competitive advantages:

1. 1Quality Assurance: Greek manufacturers adhere to stringent EU GMP standards, ensuring high-quality products.
2. 2Specialized Formulations: Greece offers unique dosage forms and combinations not readily available from other suppliers.
3. 3Regulatory Compliance: Greek products meet international regulatory standards, facilitating smoother import processes.

While other countries like China, Germany, and the US also supply Clindamycin formulations, Greece's focus on quality and specialized products makes it a preferred source for certain formulations.

India imports Clindamycin formulations from Greece due to:

1. 1Patented Formulations: Greece offers unique formulations protected by patents, unavailable from other sources.
2. 2Specialized Dosage Forms: Certain dosage forms, such as extended-release tablets, are exclusively produced by Greek manufacturers.
3. 3Technology-Licensed Products: Greece provides formulations developed through advanced technologies, meeting specific therapeutic needs.

These factors make Greek Clindamycin formulations a valuable addition to India's pharmaceutical market.

When compared to other origins like China, Germany, and the US, Greece offers:

1. 1Price: Competitive pricing due to efficient manufacturing processes.
2. 2Quality: High-quality standards adhering to EU regulations.